Kiwoom Securities Raises PharmaResearch Target Price to $48, Maintains Buy Rating

Kiwoom Securities has raised its target price for PharmaResearch from 430,000 won to 480,000 won, an increase of 11.6%, while maintaining its 'buy' rating. Although the company's third-quarter performance fell short of market expectations, the rapid increase in export share following the restructuring of its overseas distribution network has strengthened its long-term growth potential.


Shin Min-soo, a researcher at Kiwoom Securities, stated on November 9, "PharmaResearch has seen its export volume grow again since the second quarter of this year after restructuring its overseas distribution network in the third quarter of last year. This trend is similar to the past when CEO Son Ji-hoon led export growth after reorganizing overseas clients at Hugel."


PharmaResearch reported third-quarter sales of 171.5 billion won, a 26.7% increase compared to the same period last year, but 3.1% below market consensus. Operating profit rose by 1.2% to 62.6 billion won, yet it was 5.7% lower than expected, with an operating margin of 36.5%.


By business segment, domestic sales of medical devices remained stable at 57.1 billion won compared to the previous year. Despite seasonal downturns and poor performance in July and August, a recovery trend began in September, suggesting potential growth in the fourth quarter compared to the previous quarter. Medical device export sales reached 30 billion won, marking a 53.0% increase year-on-year.


The cosmetics division also continued its growth. Third-quarter cosmetics sales reached 62 billion won, a 76.2% increase from the same period last year. Domestic sales grew by 50.0% due to increased sales at Olive Young and expanded shipments through new distribution channels like Coupang and Silicon Two, while exports surged by 92.0% to 42.1 billion won, driven by increased shipment volumes.


Kiwoom Securities noted that exports accounted for 47.6% of PharmaResearch's total sales in the third quarter, the highest proportion ever recorded. Analysts suggest that if the increase in export share leads to price hikes, it could serve as a basis for reevaluating the company's value.


Shin added, "Despite falling short of the lowered operating profit consensus, the stock reacted positively immediately after the earnings announcement. While the KOSDAQ index dropped by 5.0%, PharmaResearch's stock rose by 4.2%, achieving an excess return of 9.2 percentage points."





* This article has been translated by AI.